JP2008515992A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008515992A5 JP2008515992A5 JP2007536867A JP2007536867A JP2008515992A5 JP 2008515992 A5 JP2008515992 A5 JP 2008515992A5 JP 2007536867 A JP2007536867 A JP 2007536867A JP 2007536867 A JP2007536867 A JP 2007536867A JP 2008515992 A5 JP2008515992 A5 JP 2008515992A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- cancer
- disease
- alkyl
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 125000003277 amino group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 150000002367 halogens Chemical group 0.000 claims 6
- 230000001154 acute effect Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 206010039491 Sarcoma Diseases 0.000 claims 3
- -1 benzo [1,4] dioxin-yl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 2
- 208000031220 Hemophilia Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 108020004485 Nonsense Codon Proteins 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 230000003511 endothelial effect Effects 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000037434 nonsense mutation Effects 0.000 claims 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 108700020463 BRCA1 Proteins 0.000 claims 1
- 102000036365 BRCA1 Human genes 0.000 claims 1
- 101150072950 BRCA1 gene Proteins 0.000 claims 1
- 108700020462 BRCA2 Proteins 0.000 claims 1
- 102000052609 BRCA2 Human genes 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 101150008921 Brca2 gene Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 201000009047 Chordoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000009798 Craniopharyngioma Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 1
- 208000036566 Erythroleukaemia Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000031206 Familial polycythaemia Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000000913 Kidney Calculi Diseases 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000001826 Marfan syndrome Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 claims 1
- 206010029148 Nephrolithiasis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000037550 Primary familial polycythemia Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000020221 Short stature Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000022292 Tay-Sachs disease Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000014070 Vestibular schwannoma Diseases 0.000 claims 1
- 208000027276 Von Willebrand disease Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 208000004064 acoustic neuroma Diseases 0.000 claims 1
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 claims 1
- 208000036676 acute undifferentiated leukemia Diseases 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 208000005980 beta thalassemia Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 208000002445 cystadenocarcinoma Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 201000005577 familial hyperlipidemia Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 201000002222 hemangioblastoma Diseases 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 1
- 230000001926 lymphatic effect Effects 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 208000001611 myxosarcoma Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 208000025189 neoplasm of testis Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 210000003757 neuroblast Anatomy 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 210000004560 pineal gland Anatomy 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000006870 primary polycythemia Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000018964 sebaceous gland cancer Diseases 0.000 claims 1
- 210000001599 sigmoid colon Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 201000008759 sweat gland cancer Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000000304 vasodilatating effect Effects 0.000 claims 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61763304P | 2004-10-13 | 2004-10-13 | |
| US61765504P | 2004-10-13 | 2004-10-13 | |
| US61763404P | 2004-10-13 | 2004-10-13 | |
| US61765304P | 2004-10-13 | 2004-10-13 | |
| US61767004P | 2004-10-13 | 2004-10-13 | |
| US62417004P | 2004-11-03 | 2004-11-03 | |
| PCT/US2005/036764 WO2006044505A2 (en) | 2004-10-13 | 2005-10-13 | Compounds for nonsense suppression, and methods for their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008515992A JP2008515992A (ja) | 2008-05-15 |
| JP2008515992A5 true JP2008515992A5 (enExample) | 2008-11-27 |
Family
ID=35517967
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007536837A Pending JP2008515985A (ja) | 2004-10-13 | 2005-10-13 | ナンセンス抑制の化合物とその使用方法 |
| JP2007536865A Pending JP2008515990A (ja) | 2004-10-13 | 2005-10-13 | ナンセンス抑制のための化合物およびその使用方法 |
| JP2007536867A Pending JP2008515992A (ja) | 2004-10-13 | 2005-10-13 | 体細胞変異に起因する疾患の阻止／治療用医薬を製造するための規定化合物の使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007536837A Pending JP2008515985A (ja) | 2004-10-13 | 2005-10-13 | ナンセンス抑制の化合物とその使用方法 |
| JP2007536865A Pending JP2008515990A (ja) | 2004-10-13 | 2005-10-13 | ナンセンス抑制のための化合物およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (10) | US9051342B2 (enExample) |
| EP (13) | EP2363129A1 (enExample) |
| JP (3) | JP2008515985A (enExample) |
| KR (3) | KR20070067165A (enExample) |
| AU (3) | AU2005295730A1 (enExample) |
| BR (2) | BRPI0515995A (enExample) |
| CA (5) | CA2583971A1 (enExample) |
| IL (3) | IL182464A0 (enExample) |
| MX (3) | MX2007004487A (enExample) |
| SG (2) | SG156641A1 (enExample) |
| WO (5) | WO2006044456A1 (enExample) |
Families Citing this family (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927791B2 (en) | 2002-07-24 | 2011-04-19 | Ptc Therapeutics, Inc. | Methods for identifying small molecules that modulate premature translation termination and nonsense mediated mRNA decay |
| PT3345895T (pt) | 2003-04-11 | 2020-01-29 | Ptc Therapeutics Inc | Composto de ácido 1,2,4-oxadiazole benzóico e a sua utilização para a supressão sem sentido e tratamento de doenças |
| WO2006044456A1 (en) * | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
| US20080312303A1 (en) * | 2005-10-14 | 2008-12-18 | Neurosearch A/S | Imidazole Derivatives and Their Use for Modulating the Gabaa Receptor Complex |
| US20090304641A1 (en) | 2005-10-17 | 2009-12-10 | Children's Hospital Boston | Methods and Compositions for Regulating Gene Expression |
| CA2641880C (en) * | 2006-02-10 | 2014-09-09 | Summit Corporation Plc | Treatment of duchenne muscular dystrophy |
| US9289398B2 (en) | 2006-03-30 | 2016-03-22 | Ptc Therapeutics, Inc. | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| ES2580803T3 (es) | 2006-04-07 | 2016-08-26 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
| US7863456B2 (en) * | 2006-09-25 | 2011-01-04 | Ptc Therapeutics, Inc. | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-YL]-benzoic acid |
| KR100858357B1 (ko) * | 2006-10-02 | 2008-09-11 | (주) 디지탈바이오텍 | 벤조퓨란계 유도체 화합물을 유효성분으로 함유하는인지기능 장애의 예방 및 치료용 조성물 |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| WO2008157407A2 (en) * | 2007-06-13 | 2008-12-24 | University Of Virginia Patent Foundation | Thiadiazole, oxadiazole and triazole derivatives for treating leukemia |
| TW200911237A (en) | 2007-08-03 | 2009-03-16 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| WO2009049159A1 (en) | 2007-10-10 | 2009-04-16 | Parion Sciences, Inc. | Delivering osmolytes by nasal cannula |
| CA2705562C (en) | 2007-11-16 | 2016-05-17 | Vertex Pharmaceuticals Incorporated | Isoquinoline modulators of atp-binding cassette transporters |
| ES2611077T3 (es) | 2007-12-07 | 2017-05-04 | Vertex Pharmaceuticals Incorporated | Forma solida de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) ciclopropanocarboxamida)-3-metilpiridin-2-il) benzoico |
| EP2271621B1 (en) | 2008-03-31 | 2013-11-20 | Vertex Pharmaceuticals Incorporated | Pyridyl derivatives as cftr modulators |
| JP5369854B2 (ja) | 2008-04-21 | 2013-12-18 | 住友化学株式会社 | 有害節足動物防除組成物および縮合複素環化合物 |
| ES2554772T3 (es) | 2008-05-30 | 2015-12-23 | Merck Sharp & Dohme Corp. | Azabenzoxazoles sustituidos novedosos |
| TW201000099A (en) | 2008-06-20 | 2010-01-01 | Amgen Inc | S1P1 receptor agonists and use thereof |
| KR101273765B1 (ko) * | 2008-06-24 | 2013-06-12 | 아이알엠 엘엘씨 | Ｇ 단백질-커플링된 수용체를 조정하는 화합물 및 방법 |
| US9006454B2 (en) * | 2009-04-02 | 2015-04-14 | Merck Serono S.A. | Dihydroorotate dehydrogenase inhibitors |
| WO2011022393A2 (en) * | 2009-08-17 | 2011-02-24 | The Brigham And Women's Hospital, Inc. | Phosphatidylcholine transfer protein inhibitors |
| BR112012006956A2 (pt) | 2009-10-12 | 2015-09-15 | Bayer Cropscience Ag | 1- (pirida-3-il) -pirazóisol e 1- (pirimida-5-il) - pirazóisol como pesticidas |
| CA2786424A1 (en) * | 2010-01-08 | 2011-07-14 | Ruga Corporation | Raf kinase inhibitors |
| MX345541B (es) | 2010-03-25 | 2017-02-03 | Vertex Pharma | Formas solidas de (r)-1(2,2-difluorobenzo[d] [1,3]dioxol-5-il)-n-( 1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il) -1h-indol-5-il) ciclopropanocarboxamida. |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| CA2795748C (en) | 2010-04-07 | 2020-12-08 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| PL3150198T3 (pl) | 2010-04-07 | 2022-01-17 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksamido)-3-metylopirydyn-2-ylo)benzoesowego i ich podawanie |
| KR20190061096A (ko) | 2010-04-22 | 2019-06-04 | 버텍스 파마슈티칼스 인코포레이티드 | 시클로알킬카르복스아미도-인돌 화합물의 제조 방법 |
| KR101799429B1 (ko) * | 2010-05-03 | 2017-11-21 | 에스케이바이오팜 주식회사 | 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물 |
| US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| JP2013536231A (ja) | 2010-08-23 | 2013-09-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | （ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与 |
| EP4108671B1 (en) | 2010-10-01 | 2024-11-20 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
| US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
| WO2012170677A1 (en) | 2011-06-07 | 2012-12-13 | Parion Sciences, Inc. | Methods of treatment |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| ES2911677T3 (es) | 2011-10-03 | 2022-05-20 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos |
| AU2012335714B2 (en) | 2011-11-08 | 2017-04-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| MX2014007233A (es) | 2011-12-16 | 2015-02-04 | Moderna Therapeutics Inc | Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados. |
| ME03464B (me) | 2012-01-25 | 2020-01-20 | Vertex Pharma | Formulacije 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline |
| KR101452235B1 (ko) * | 2012-02-03 | 2014-10-22 | 서울대학교산학협력단 | 신규한 피리미딘계 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 ｒａｇｅ 수용체 관련 질환의 예방 또는 치료용 약학적 조성물 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| CA2868391A1 (en) | 2012-04-02 | 2013-10-10 | Stephane Bancel | Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| RS58043B1 (sr) | 2012-04-24 | 2019-02-28 | Vertex Pharma | Inhibitori dna-pk |
| KR102109223B1 (ko) | 2012-05-29 | 2020-05-11 | 패리온 사이언스 인코퍼레이티드 | 안구 건조 및 다른 점막 질환의 치료를 위한 나트륨 채널 차단제 활성을 보유하는 덴드리머 유사 아미노 아미드 |
| CA2878057A1 (en) | 2012-07-16 | 2014-01-23 | Rossitza Gueorguieva Alargova | Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| ES3009747T3 (en) | 2012-11-02 | 2025-03-31 | Vertex Pharma | Pharmaceutical compositions for the treatment of cftr mediated diseases |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| MX2015007205A (es) | 2012-12-06 | 2016-03-31 | Quanticel Pharmaceuticals Inc | Inhibidores de la desmetilasa de histona. |
| EP2931712B8 (en) | 2012-12-17 | 2018-05-23 | Parion Sciences, Inc. | 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds |
| CA2896686A1 (en) | 2012-12-17 | 2014-06-26 | Parion Sciences, Inc. | 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds |
| SG11201504799QA (en) | 2012-12-17 | 2015-07-30 | Parion Sciences Inc | Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration |
| EP3985003B1 (en) | 2013-03-12 | 2023-08-09 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| WO2014163934A1 (en) * | 2013-03-13 | 2014-10-09 | Dow Agrosciences Llc | Preparation of 1,3-(substituted-diaryl)-1,2,4-triazoles |
| JP6348568B2 (ja) * | 2013-03-15 | 2018-06-27 | モンサント テクノロジー エルエルシー | 線虫害虫防除のためのｎ−，ｃ−二置換アゾール |
| MX372775B (es) | 2013-03-15 | 2020-06-29 | Discoverybiomed Inc | Derivados de cumarina y métodos de uso en el tratamiento de la fribosis quística, enfermedad pulmonar obstructiva crónica y trastornos de proteínas mal plegadas. |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| HK1218537A1 (zh) | 2013-03-15 | 2017-02-24 | Discoverybiomed Inc. | 香豆素衍生物以及用於治疗过度增生性疾病的方法 |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| FR3011468B1 (fr) * | 2013-10-04 | 2015-12-04 | Inventiva | Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose |
| WO2015054283A1 (en) * | 2013-10-08 | 2015-04-16 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| PE20161022A1 (es) | 2013-10-17 | 2016-11-12 | Vertex Pharma | Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5´-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteinas quinasa dependientes de adn |
| KR20230024431A (ko) | 2014-03-06 | 2023-02-20 | 피티씨 테라퓨틱스, 인크. | 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염 |
| US10206877B2 (en) | 2014-04-15 | 2019-02-19 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
| US20170210788A1 (en) | 2014-07-23 | 2017-07-27 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| TWI735416B (zh) | 2014-10-06 | 2021-08-11 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| WO2016087936A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Substituted pyridinones as bromodomain inhibitors |
| AU2015367531B2 (en) * | 2014-12-17 | 2020-04-30 | King's College London | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARbeta) agonists |
| US10647688B2 (en) * | 2014-12-19 | 2020-05-12 | Galderma Research & Development | Compounds, synthesis method thereof and use of same in medicine and in cosmetics |
| EP3237413A4 (en) | 2014-12-23 | 2018-09-12 | FGH Biotech | Compositions of fatostatin based heterocyclic compounds and uses thereof |
| CN107849027B (zh) * | 2015-07-24 | 2021-03-12 | 先正达参股股份有限公司 | 具有含硫取代基的杀有害生物活性1,2,4-三唑衍生物 |
| JP2018531975A (ja) | 2015-10-30 | 2018-11-01 | ピーティーシー セラピューティクス，インコーポレーテッド | てんかんの治療方法 |
| CA3006911C (en) | 2015-12-22 | 2024-09-10 | Syngenta Participations Ag | Pesticidally active pyrazole derivatives |
| CA3048193A1 (en) | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response by promoting premature termination codon read-through |
| JP6931695B2 (ja) | 2016-04-29 | 2021-09-08 | エフジーエイチ バイオテック，インコーポレーテッド | 疾患の治療のための二置換ピラゾール化合物 |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| PT3730487T (pt) | 2016-06-13 | 2022-07-22 | Gilead Sciences Inc | Derivados de azetidina como moduladores de fxr (nr1h4) |
| GB201610867D0 (en) | 2016-06-22 | 2016-08-03 | King S College London | Crystalline forms of a therapeutic compound and processes for their preparation |
| JP7071981B2 (ja) | 2016-09-07 | 2022-05-19 | エフジーエイチ バイオテック，インコーポレーテッド | 疾患の治療のための二置換ピラゾール化合物 |
| CA3038657A1 (en) | 2016-09-27 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors |
| KR102599339B1 (ko) * | 2016-12-20 | 2023-11-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제로서 유용한 화합물 |
| US20180280394A1 (en) | 2017-03-28 | 2018-10-04 | Gilead Sciences, Inc. | Methods of treating liver disease |
| WO2018187479A1 (en) * | 2017-04-04 | 2018-10-11 | Case Western Reserve University | Method of modulating ribonucleotide reductase |
| CA3066423A1 (en) * | 2017-06-14 | 2018-12-20 | Trevena, Inc. | Compounds for modulating s1p1 activity and methods of using the same |
| EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
| JP2020525434A (ja) | 2017-06-22 | 2020-08-27 | ムーンショット ファーマ エルエルシー | アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法 |
| WO2019040724A1 (en) * | 2017-08-23 | 2019-02-28 | The Regents Of The University Of Michigan | SMALL MYC INHIBITOR MOLECULES AND USES THEREOF |
| CA3073211A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| WO2019101709A1 (en) | 2017-11-23 | 2019-05-31 | Universita' Degli Studi Di Palermo | Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations |
| WO2019124577A1 (ko) * | 2017-12-20 | 2019-06-27 | 재단법인 경기도경제과학진흥원 | 트리아졸 유도체 및 이의 용도 |
| CN112074897B (zh) * | 2018-03-29 | 2025-01-28 | 艾克斯普罗工程股份公司 | 用于产生高振幅的压力波的设备和方法 |
| WO2019209777A1 (en) * | 2018-04-23 | 2019-10-31 | The Curators Of The University Of Missouri | Improved crispr therapy |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| DK3911647T3 (da) | 2019-01-15 | 2024-02-26 | Gilead Sciences Inc | Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan |
| CN113439078B (zh) | 2019-02-19 | 2024-04-23 | 吉利德科学公司 | Fxr激动剂的固体形式 |
| PH12021552358A1 (en) * | 2019-03-26 | 2022-09-05 | Neuropore Therapies Inc | Compounds and compositions as modulators of tlr signaling |
| KR102663365B1 (ko) * | 2019-09-25 | 2024-05-08 | 한국원자력의학원 | 신규 트리플루오로메틸페닐피라졸 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물 |
| WO2021060888A2 (ko) * | 2019-09-25 | 2021-04-01 | 한국원자력의학원 | 신규 트리플루오로메틸페닐피라졸 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물 |
| WO2021101854A1 (en) | 2019-11-19 | 2021-05-27 | Trevena, Inc. | Compounds and methods of preparing compounds s1p1 modulators |
| EP4073055A4 (en) | 2019-12-10 | 2024-02-28 | The Trustees of Indiana University | REPLICATION PROTEIN A (RPA)-DNA INTERACTION INHIBITORS |
| KR102847693B1 (ko) * | 2019-12-27 | 2025-08-18 | 서울대학교산학협력단 | 옥사디아졸 유도체를 포함하는 비만의 예방 또는 치료용 조성물 |
| EP3912628A1 (en) | 2020-05-20 | 2021-11-24 | Institut de Recherche en Semiochimie et Ethologie Appliquée | Nucleoside analogues to inhibit the main protease of a coronavirus |
| CN117042759A (zh) * | 2021-02-04 | 2023-11-10 | 国立大学法人九州大学 | Il-31产生抑制剂和含有它的药物组合物 |
| CN119350257B (zh) * | 2021-06-28 | 2025-11-18 | 广西医科大学 | 三氮唑化合物 |
| EP4173485A1 (en) * | 2021-10-27 | 2023-05-03 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Protein aggregation inhibiting compounds for plant disease control |
| AU2023238460A1 (en) * | 2022-03-25 | 2024-10-31 | Vasthera Co., Ltd. | 3-phenylisoxazole derivative, and pharmaceutical composition for preventing or treating eye disease, containing same as active ingredient |
| CN120303267A (zh) | 2022-11-03 | 2025-07-11 | 森托尼克思有限公司 | 针对tau聚集体的选择性配体 |
| GB202300021D0 (en) * | 2023-01-03 | 2023-02-15 | Thirtyfivebio Ltd | Compounds |
| WO2025116596A1 (ko) * | 2023-11-29 | 2025-06-05 | 가천대학교 산학협력단 | 신규 화합물 및 이를 포함하는 안질환 예방 또는 치료용 조성물 |
| CN119144004B (zh) * | 2024-08-12 | 2025-10-28 | 兰州大学 | 一种m-hof材料及其制备方法和在氢氧根离子识别中的应用 |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3153017A (en) * | 1961-06-29 | 1964-10-13 | Eastman Kodak Co | Nitrogen-containing linear polyesters from amino methyl cyclohexanol and dicarboxylic acids |
| CH489510A (de) | 1967-02-07 | 1970-04-30 | Geigy Ag J R | Verfahren zur Herstellung von substituierten v-Triazolen |
| GB1263940A (en) * | 1968-08-02 | 1972-02-16 | Innothera Lab Sa | 0-phenyl-pyrroles |
| GB1248070A (en) | 1968-12-16 | 1971-09-29 | Science Union & Cie | Thiazolyl-benzoic acid derivatives and process for preparing them |
| US3803162A (en) | 1969-10-03 | 1974-04-09 | Sandoz Ltd | 7-triazolyl-3-phenylcoumarins |
| US3679669A (en) * | 1970-09-23 | 1972-07-25 | Ciba Geigy Ag | Phenyl-1,3,4-oxdiazole compounds |
| US3882138A (en) * | 1971-08-09 | 1975-05-06 | Uniroyal Inc | Oxazole and oxadiazole benzoic acid derivatives as herbicides |
| US3964896A (en) | 1971-08-09 | 1976-06-22 | Uniroyal, Inc. | Oxadiazole benzoic acid derivatives as herbicides |
| BE789948A (fr) * | 1971-10-13 | 1973-04-11 | Sandoz Sa | Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments |
| US3948937A (en) * | 1972-02-29 | 1976-04-06 | E. I. Du Pont De Nemours And Company | Pyrazole plant growth regulants |
| US3947263A (en) * | 1974-07-29 | 1976-03-30 | Uniroyal, Inc. | Plant growth regulants |
| US4035175A (en) * | 1974-07-29 | 1977-07-12 | Uniroyal Inc. | Method of retarding the growth of plants using certain oxadiazolyl, oxazolyl or thiadiazolyl benzoic acid derivatives |
| AU497898B2 (en) | 1975-01-10 | 1979-01-18 | Commonwealth Scientific And Industrial Research Organisation | Plant growth regulating method and composition for use therein |
| US4038285A (en) * | 1975-06-25 | 1977-07-26 | E. I. Du Pont De Nemours And Company | 1-(2-carboxyaryl)-4-arylimidazoles and 1-(2-carboxyaryl)-3-aryl-1,2,4-triazoles |
| US4032644A (en) * | 1975-12-29 | 1977-06-28 | Sandoz, Inc. | Isoxazolyl benzoic acids |
| DE2722331A1 (de) | 1976-05-18 | 1977-11-24 | Ricoh Kk | 1,3,4-oxadiazolderivate sowie diese enthaltende elektrophotographische aufzeichnungsmaterialien |
| US4140515A (en) | 1977-05-12 | 1979-02-20 | Monsanto Company | Aryl-3-isoxazole benzoates as plant growth regulants and herbicides |
| US4166732A (en) * | 1977-05-12 | 1979-09-04 | Monsanto Company | Oxadiazol-5-yl-benzoates |
| US4135910A (en) * | 1977-05-12 | 1979-01-23 | Monsanto Company | Oxadiazol-3-yl-benzoates as plant growth regulants |
| US4210762A (en) * | 1978-08-17 | 1980-07-01 | Monsanto Company | 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates |
| US4268299A (en) * | 1978-08-17 | 1981-05-19 | Monsanto Company | Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates |
| CA1125768A (en) * | 1978-10-31 | 1982-06-15 | Hoffmann-La Roche Limited | Benzoxazole derivatives |
| US4229204A (en) * | 1978-12-04 | 1980-10-21 | Monsanto Company | Trifluoromethylphenyl isoxazolyl benzoates |
| JPS58177977A (ja) * | 1982-04-09 | 1983-10-18 | Grelan Pharmaceut Co Ltd | ４−フエニルピラゾ−ル類 |
| SU1063100A1 (ru) * | 1982-04-22 | 1985-06-30 | Предприятие П/Я А-7850 | Жидкокристаллический материал дл электрооптических устройств |
| US4760066A (en) * | 1982-09-21 | 1988-07-26 | Wayne State University | Method for treating human tumor cell metastasis |
| US4546113A (en) * | 1983-04-14 | 1985-10-08 | Pfizer Inc. | Antiprotozoal diamidines |
| DD226883A1 (de) * | 1984-07-30 | 1985-09-04 | Neubauer T Paedagog Hochschule | Verfahren zur herstellung von 1,3-disubstituierten 5-alkoxy-1,2,4-triazolen und 1,2,4-triazolin-5-onen |
| US5436252A (en) * | 1986-12-19 | 1995-07-25 | Merrell Dow Pharmaceuticals Inc. | 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| DE3819037A1 (de) | 1988-06-04 | 1989-12-14 | Hoechst Ag | 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden |
| US5260451A (en) * | 1989-05-11 | 1993-11-09 | Merckle Gmbh | Substituted pyrrole compounds and use thereof in pharmaceutical compositions |
| US5022915A (en) * | 1990-03-01 | 1991-06-11 | Ici Americas Inc. | Substituted 2,4-diarylpyrimidines and their use as herbicides |
| SG86971A1 (en) | 1990-11-30 | 2002-03-19 | Teijin Ltd | 2-arylthiazole derivatives and pharmaceutical composition thereof |
| FR2672050A1 (fr) * | 1991-01-30 | 1992-07-31 | Atochem | Diaryl-2,5 oxadiazoles-1,3,4 hydroxyester, hydroxyacide et acetoxyacide, leur procede de synthese. |
| WO1993025673A1 (en) | 1992-06-04 | 1993-12-23 | The Regents Of The University Of California | In vivo gene therapy with intron-free sequence of interest |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| IL112290A (en) * | 1994-01-12 | 1999-01-26 | Novartis Ag | Transformed aryl and the troiryl pyrimidines and herbicides containing them |
| US5521189A (en) | 1994-05-06 | 1996-05-28 | The University Of Nc At Ch | Methods of treating pneumocystis carinii pneumonia |
| US5486534A (en) | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
| JP2897427B2 (ja) * | 1994-10-07 | 1999-05-31 | 藤沢薬品工業株式会社 | 抗微生物活性を有する環状ヘキサペプチド化合物 |
| US5681746A (en) | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
| JP3964478B2 (ja) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬 |
| DE19536811A1 (de) | 1995-10-02 | 1997-04-03 | Basf Ag | Zwischenprodukte und Verfahren zur Herstellung von substituierten Salicylsäurederivaten als Pflanzenschutzmittel |
| JP3995716B2 (ja) * | 1996-03-18 | 2007-10-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 縮合環含有カルボン酸誘導体 |
| DE19620041A1 (de) * | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| TW467902B (en) * | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
| MY128323A (en) | 1996-09-30 | 2007-01-31 | Otsuka Pharma Co Ltd | Thiazole derivatives for inhibition of cytokine production and of cell adhesion |
| AU4945697A (en) | 1996-10-09 | 1998-05-05 | Novartis Ag | Solid phase synthesis of heterocyclic compounds |
| WO1998023611A1 (en) * | 1996-11-25 | 1998-06-04 | The Procter & Gamble Company | 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists |
| AU5802798A (en) | 1996-12-20 | 1998-07-17 | Human Genome Sciences, Inc. | Human oncogene induced secreted protein i |
| SI1023063T1 (en) * | 1997-10-06 | 2004-02-29 | Abbott Gmbh & Co. Kg | INDENO(1,2-c), NAPHTHO(1,2-c)- AND BENZO(6,7)CYCLOHEPTA(1,2-c)PYRAZOLE DERIVATIVES |
| ATE249217T1 (de) | 1997-10-06 | 2003-09-15 | Abbott Gmbh & Co Kg | Indeno(1,2-c)-,naphtho(1,2-c)-und benzo(6, 7)cyclohepta(1,2-c)pyrazolderivate |
| DE19816880A1 (de) | 1998-04-17 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| HUP0102515A3 (en) * | 1998-02-09 | 2001-12-28 | Fujisawa Pharmaceutical Co | Cyclopeptides, process for their preparation, pharmaceutical compositions comprising thereof and their use |
| AU4005299A (en) * | 1998-05-19 | 1999-12-06 | Regents Of The University Of California, The | Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis |
| ATE315033T1 (de) | 1998-08-07 | 2006-02-15 | Chiron Corp | Subtituierte isoxazole derivate als estrogen rezeptor modulatore |
| DE19904389A1 (de) * | 1999-02-04 | 2000-08-10 | Bayer Ag | Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe |
| DE19904406A1 (de) | 1999-02-04 | 2000-08-10 | Bayer Ag | Substituierte Pyrazolcarbonsäuren |
| CA2393821C (en) | 1999-12-16 | 2009-05-26 | Schering Corporation | Substituted imidazole neuropeptide y y5 receptor antagonists |
| US7729756B2 (en) | 2000-01-18 | 2010-06-01 | Siemens Aktiengesellschaft | Measurement system for examining a section of tissue on a patient and the use of a measurement system of this type |
| ES2330918T3 (es) | 2000-02-11 | 2009-12-17 | Genentech, Inc. | Inhibidor del activador del factor de crecimiento de hepatocitos para usar en la modulacion de la angiogenesis y la cardiovascularizacion. |
| US6605615B2 (en) * | 2000-03-01 | 2003-08-12 | Tularik Inc. | Hydrazones and analogs as cholesterol lowering agents |
| GB0012362D0 (en) * | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
| AU5741301A (en) | 2000-05-22 | 2001-12-03 | Aventis Pharm Prod Inc | Arylmethylamine derivatives for use as tryptase inhibitors |
| WO2002036580A2 (en) * | 2000-10-31 | 2002-05-10 | Lynn Bonham | Benzoxazole lpaat- beta inhibitors and uses thereof |
| DK1379525T3 (da) * | 2001-02-21 | 2007-12-27 | Astrazeneca Ab | Heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamatreceptor-antagonister |
| AUPR362001A0 (en) | 2001-03-08 | 2001-04-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| JP2003026663A (ja) * | 2001-05-09 | 2003-01-29 | Takeda Chem Ind Ltd | アゾール化合物、その製造法および用途 |
| EP1386915A4 (en) | 2001-05-09 | 2004-11-10 | Sumitomo Chem Takeda Agro Co | AZOL COMPOUNDS, METHOD FOR THE PRODUCTION AND USE THEREOF |
| US7223791B2 (en) * | 2001-06-26 | 2007-05-29 | Takeda Pharmaceutical Company Limited | Function regulator for retinoid relative receptor |
| JP2003081832A (ja) * | 2001-06-26 | 2003-03-19 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
| DE10136066A1 (de) | 2001-07-25 | 2003-02-13 | Bayer Cropscience Ag | Tetrahydropyridazin-Derivate |
| US20070010562A1 (en) * | 2001-08-13 | 2007-01-11 | Ulrike Bauer | Nr1h4 nuclear receptor binding compounds |
| JP2005532983A (ja) * | 2001-09-26 | 2005-11-04 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | Ｃ１７，２０リアーゼ阻害剤としての３‐ピリジルもしくは４‐イソキノリニルチアゾール |
| EP1458383B1 (en) | 2001-12-18 | 2007-11-21 | Merck & Co., Inc. | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| ES2292854T3 (es) * | 2001-12-18 | 2008-03-16 | MERCK & CO., INC. | Moduladores triazol sustituidos con heteroarilo del receptor-5 metabotropico de glumatamato. |
| JP4357965B2 (ja) * | 2001-12-21 | 2009-11-04 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−５のヘテロアリール置換ピロールモジュレーター |
| JP2005529923A (ja) * | 2002-05-13 | 2005-10-06 | イーライ・リリー・アンド・カンパニー | 肥満および糖尿病の治療におけるメラニン凝集ホルモンアンタゴニストとして使用するための多環式化合物 |
| EP1506175B1 (en) * | 2002-05-15 | 2009-04-01 | Janssen Pharmaceutica N.V. | N-substituted tricyclic 3-aminopyrazoles as pdgf receptor inhibitors |
| ATE548354T1 (de) * | 2002-07-24 | 2012-03-15 | Ptc Therapeutics Inc | Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen |
| AU2003261237A1 (en) * | 2002-07-24 | 2004-02-09 | Ptc Therapeutics, Inc. | Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases |
| AU2003254157A1 (en) * | 2002-07-24 | 2004-02-09 | Ptc Therapeutics, Inc. | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| PA8578101A1 (es) * | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
| US20060235021A1 (en) * | 2002-08-13 | 2006-10-19 | Wesley Blackaby | Phenylpyridazine derivatives as ligands for gaba receptors |
| JP2006501263A (ja) * | 2002-09-09 | 2006-01-12 | アムジエン・インコーポレーテツド | 炎症治療用のＴＮＦ−αおよびインターロイキン低下剤としての１，４，５−置換１，２−ジヒドロ−ピラゾール−３−オンおよび３−アルコキシ−１Ｈ−ピラゾール誘導体 |
| AU2003283597A1 (en) * | 2002-11-16 | 2004-06-15 | Oxford Glycosciences (Uk) Ltd | Benzoxazole, benzthiazole and benzimidazole acid derivatives and their use as heparanase inhibitors |
| US20040176264A1 (en) * | 2002-12-30 | 2004-09-09 | The Procter & Gamble Company | Rinse aid composition containing water-soluble metal salt for use in automatic dishwashing for glassware corrosion protection |
| GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| WO2004074244A2 (en) * | 2003-02-20 | 2004-09-02 | Smithkline Beecham Corporation | Pyrimidine compounds |
| US7320986B2 (en) * | 2003-03-07 | 2008-01-22 | Abbott Labortories | Fused tri and tetra-cyclic pyrazole kinase inhibitors |
| PT3345895T (pt) | 2003-04-11 | 2020-01-29 | Ptc Therapeutics Inc | Composto de ácido 1,2,4-oxadiazole benzóico e a sua utilização para a supressão sem sentido e tratamento de doenças |
| JP2006523719A (ja) | 2003-04-18 | 2006-10-19 | メモリー・ファーマシューティカルズ・コーポレイション | ホスホジエステラーゼ４抑制剤としてのピラゾール誘導体 |
| BRPI0514553A (pt) | 2004-08-23 | 2008-06-17 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir o receptor de histamina h3 em um mamìfero, para o tratamento de um distúrbio do sistema nervoso, para o tratamento de obesidade e para o tratamento de um distúrbio ou doença, e, uso de um composto ou um sal do mesmo |
| WO2006044456A1 (en) * | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
| WO2007059356A2 (en) | 2005-11-19 | 2007-05-24 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Furfurylidene- pyrazolidines and their use as inhibitors of ubiquitin e1 |
| EP2284154A1 (en) * | 2009-07-29 | 2011-02-16 | Argon Pharma S.L. | Antitumor 1,2-diphenylpyrrole compounds and their preparation process |
-
2005
- 2005-10-13 WO PCT/US2005/036673 patent/WO2006044456A1/en not_active Ceased
- 2005-10-13 US US11/577,177 patent/US9051342B2/en not_active Expired - Fee Related
- 2005-10-13 CA CA002583971A patent/CA2583971A1/en not_active Abandoned
- 2005-10-13 EP EP10185133A patent/EP2363129A1/en not_active Withdrawn
- 2005-10-13 KR KR1020077009154A patent/KR20070067165A/ko not_active Withdrawn
- 2005-10-13 SG SG200906829-7A patent/SG156641A1/en unknown
- 2005-10-13 MX MX2007004487A patent/MX2007004487A/es unknown
- 2005-10-13 WO PCT/US2005/036764 patent/WO2006044505A2/en not_active Ceased
- 2005-10-13 US US11/577,189 patent/US9315467B2/en active Active
- 2005-10-13 EP EP05815159.8A patent/EP1815206B1/en not_active Expired - Lifetime
- 2005-10-13 EP EP15168072.5A patent/EP2939674A1/en not_active Withdrawn
- 2005-10-13 MX MX2007004484A patent/MX2007004484A/es unknown
- 2005-10-13 EP EP16163831.7A patent/EP3067053A1/en not_active Withdrawn
- 2005-10-13 BR BRPI0515995-4A patent/BRPI0515995A/pt not_active IP Right Cessation
- 2005-10-13 CA CA002582885A patent/CA2582885A1/en not_active Abandoned
- 2005-10-13 JP JP2007536837A patent/JP2008515985A/ja active Pending
- 2005-10-13 SG SG200906828-9A patent/SG156640A1/en unknown
- 2005-10-13 EP EP10185126.9A patent/EP2301538B1/en not_active Expired - Lifetime
- 2005-10-13 MX MX2007004479A patent/MX2007004479A/es unknown
- 2005-10-13 WO PCT/US2005/036761 patent/WO2006044502A2/en not_active Ceased
- 2005-10-13 EP EP10185128.5A patent/EP2301536B1/en not_active Expired - Lifetime
- 2005-10-13 EP EP10185137A patent/EP2316452A1/en not_active Withdrawn
- 2005-10-13 CA CA002583177A patent/CA2583177A1/en not_active Abandoned
- 2005-10-13 BR BRPI0516110-0A patent/BRPI0516110A/pt not_active IP Right Cessation
- 2005-10-13 AU AU2005295730A patent/AU2005295730A1/en not_active Abandoned
- 2005-10-13 CA CA002583159A patent/CA2583159A1/en not_active Abandoned
- 2005-10-13 EP EP05807462A patent/EP1799212A2/en not_active Withdrawn
- 2005-10-13 CA CA002583976A patent/CA2583976A1/en not_active Abandoned
- 2005-10-13 EP EP05807667A patent/EP1799659A1/en not_active Withdrawn
- 2005-10-13 JP JP2007536865A patent/JP2008515990A/ja active Pending
- 2005-10-13 WO PCT/US2005/037052 patent/WO2006044682A1/en not_active Ceased
- 2005-10-13 EP EP05804171A patent/EP1812071A2/en not_active Withdrawn
- 2005-10-13 JP JP2007536867A patent/JP2008515992A/ja active Pending
- 2005-10-13 AU AU2005295727A patent/AU2005295727A1/en not_active Abandoned
- 2005-10-13 AU AU2005295778A patent/AU2005295778A1/en not_active Abandoned
- 2005-10-13 EP EP10185130.1A patent/EP2311455B1/en not_active Expired - Lifetime
- 2005-10-13 US US11/577,191 patent/US9611230B2/en not_active Expired - Fee Related
- 2005-10-13 US US11/577,176 patent/US20080269191A1/en not_active Abandoned
- 2005-10-13 EP EP05804194A patent/EP1799207A2/en not_active Withdrawn
- 2005-10-13 KR KR1020077010767A patent/KR20070067201A/ko not_active Withdrawn
- 2005-10-13 EP EP10185139A patent/EP2402323A3/en not_active Withdrawn
- 2005-10-13 US US11/577,192 patent/US7902235B2/en not_active Expired - Fee Related
- 2005-10-13 KR KR1020077010794A patent/KR20070065429A/ko not_active Withdrawn
- 2005-10-13 WO PCT/US2005/036762 patent/WO2006044503A2/en not_active Ceased
-
2007
- 2007-04-11 IL IL182464A patent/IL182464A0/en unknown
- 2007-04-11 IL IL182459A patent/IL182459A0/en unknown
- 2007-04-11 IL IL182461A patent/IL182461A0/en unknown
-
2011
- 2011-03-07 US US13/042,456 patent/US8710031B2/en not_active Expired - Fee Related
-
2014
- 2014-04-28 US US14/263,478 patent/US9273076B2/en not_active Expired - Lifetime
-
2015
- 2015-06-08 US US14/733,615 patent/US20150274674A1/en not_active Abandoned
-
2016
- 2016-04-15 US US15/130,318 patent/US20160229818A1/en not_active Abandoned
-
2017
- 2017-03-31 US US15/475,240 patent/US20170204073A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008515992A5 (enExample) | ||
| JP2008515990A5 (enExample) | ||
| JP2008515985A5 (enExample) | ||
| JP2005526723A5 (enExample) | ||
| JP2002525267A (ja) | アゼチジン誘導体、それらの製造およびそれらを含有する薬剤 | |
| RU2020108515A (ru) | Соединения и способы целевого расщепления андрогенного рецептора | |
| JP2019518766A5 (enExample) | ||
| JP2010053153A (ja) | Ｃｂ１受容体拮抗剤の経口用医薬組成物 | |
| JP2012515724A5 (enExample) | ||
| JP2010505832A5 (enExample) | ||
| JP2007508360A5 (enExample) | ||
| JP2007505922A5 (enExample) | ||
| WO2001064633A1 (fr) | Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation | |
| JP2004137288A5 (enExample) | ||
| JP2006506466A5 (enExample) | ||
| TW201121544A (en) | Novel phenol derivative | |
| TW201016692A (en) | Novel compounds as cannabinoid receptor ligands | |
| JP2005505586A5 (enExample) | ||
| CN105218532B (zh) | 苯并三氮唑类化合物、制备方法和其医药用途 | |
| JP2008503489A5 (enExample) | ||
| JP2010506919A5 (enExample) | ||
| JP2017520600A5 (enExample) | ||
| JP2004525184A5 (enExample) | ||
| JP2014501232A5 (enExample) | ||
| JP2008519049A5 (enExample) |